Table 1:

Inclusion and exclusion criteria.

Inclusion criteria

Exclusion criteria

– Histologically or cytologically verified gastrointestinal or ovarian cancer or primary peritoneal malignancy (based on tissue from the primary tumor and/or its metastases)– Ovarian cancer patients must be platinum resistant and have completed at least one line of chemotherapy for platinum-resistant disease– Radiological, histological or cytological evidence of PC– No indication for CRS and HIPEC (according to National Guidelines).– Performance status 0–1– No more than one extraperitoneal metastasis– Age>18 years– Females must be post-menopausal– Written informed consent

– Symptomatic small bowel obstruction (i.e. total parenteral nutrition, nasogastric tube)– Previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones– A history of allergic reaction to platinum containing compounds or doxorubicin– Renal impairment, defined as glomerular filtration rate (GFR)<40 mL/min, (Cockcroft-Gault Equation)– Myocardial insufficiency, defined as NYHA class>2– Impaired liver function defined as bilirubin ≥1.5×UNL (upper normal limit)– Inadequate hematological function defined as ANC ≤1.5×109/L and platelets ≤100×109/L